In summary, in the Col4α3 knockout murine model of CKD, we observed that treatment with 1% FC—a lower dose than previously reported—decreased serum phosphate concentrations, increased iron parameters, substantially reduced circulating FGF23 levels, decreased markers of systemic and kidney inflammation, improved kidney function, and decreased kidney fibrosis. Here, COL4A3 is linked to nephritis.